Skip to main content
OpenTrials
Completed

NCT Number: NCT03281512

Saturated Fatty Acids Intake and Mortality, Diabetes, Hypertension and Overweight

The role of saturated fatty acids (SFAs) intake in the development of total death, cardiovascular diseases, diabetes, hypertension and overweight are in great controversy but evidence from large population in China is scant.The investigators aim to use the data from the China Health and Nutrition Survey to assess the long-term association of SFAs intake with total mortality, diabetes, hypertension and overweight.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Morality Body Weight Cardiovascular Diseases Diabetes Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Hypertension Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms Vascular Diseases

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

The role of saturated fatty acids (SFAs) intake in the development of total death, diabetes, hypertension and overweight are in great controversy but evidence from large population in China is lacking.The investigators aim to utilize the data from the China Health and Nutrition Survey. The investigators will calculate the cumulative average intake of SFAs based on 3 consecutive 24-h dietary recalls in each round.Sex-specific Cox regression models will be used to estimate the relative risk.Results from our work will be used to provide epidemiological evidence for improving recommendation on SFAs intake for Chinese in dietary guidelines.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged ≥20 with complete data on diet and follow-up time

Exclusion criteria

  • Cardiovascular diseases
  • Diabetes (for analyses of diabetes)
  • Body mass index ≥ 24 kg/㎡ (for analyses of overweight)
  • Hypertension (for analyses of hypertension)

Treatment and study plan

Primary outcomes

  1. Mortality

    Time frame: From baseline until death or censoring on 31 December 2011, whichever came first, assessed up to an average of 10 years

    Incidence of all-cause death, on basis of household members' report

  2. Diabetes

    Time frame: From entry into the study (baseline: 1997-2009) until 2011

    Incidence of diabetes, on basis of self-reported physician diagnosis, fasting plasma glucose ≥ 7.0 mmol/l or HbA1c ≥ 6.5%

Secondary outcomes

  1. Saturated fatty acids intake

    Time frame: From entry into the study (baseline: 1997-2009) until 2011

    Cumulative average intake of saturated fatty acids on basis of 3 consecutive 24-h dietary recalls

  2. Hypertension

    Time frame: From entry into the study (baseline: 1997-2009) until 2011

    Incidence of hypertension, on basis of self-reported physician diagnosis, systolic pressure ≥ 140 mmHg or diastolic pressure ≥ 90 mmHg

  3. Overweight

    Time frame: From entry into the study (baseline: 1997-2009) until 2011

    Incidence of overweight, on basis of body mass index (BMI), BMI ≥ 24 kg/㎡

Sponsors and collaborators

Lead sponsor

Zhejiang University

Other

Collaborators

  • National Institute of Health and Nutrition

Registry information

Official study title

Saturated Fatty Acids Intake and Mortality, Diabetes, Hypertension and Overweight in the China Health and Nutrition Survey (CHNS)

Important dates

Study start
1989
Primary completion
2011
Study completion
2012
First posted
Sep 13, 2017
Registry last updated
Mar 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.